• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

IGFBP-2作为非酒精性脂肪性肝病的生物标志物可改善肝脂肪变性:一项综合生物信息学与实验研究

IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study.

作者信息

Chen Xu, Tang Yi, Chen Shen, Ling Wenhua, Wang Qing

机构信息

Department of Toxicology, School of Public Health, Sun Yat-sen University, Guangzhou, People's Republic of China.

Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou, People's Republic of China.

出版信息

Endocr Connect. 2021 Oct 13;10(10):1315-1325. doi: 10.1530/EC-21-0353.

DOI:10.1530/EC-21-0353
PMID:34524971
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8562889/
Abstract

BACKGROUND AND AIMS

Non-alcoholic fatty liver disease (NAFLD) has become a common chronic liver disease in the world. Simple steatosis (SS) is the early phase of NAFLD. However, the molecular mechanisms underlying the development of steatosis have not yet been fully elucidated.

METHODS

Two public datasets (GSE48452 and GSE89632) through the Gene Expression Omnibus (GEO) database were used to identify differentially expressed genes (DEGs) in the development of steatosis. A total of 72 participants including 38 normal histological controls and 34 SS patients were included in this study. Gene ontology (GO), Kyoto Encyclopedia of Genes and Genomes (KEGG), and protein-protein interaction (PPI) network analysis were performed to explore the function of DEGs. The results were further confirmed in high-fat diet (HFD)-fed mice and oleate-treated HepG2 cells.

RESULTS

Total 57 DEGs including 31 up- and 26 down-regulated genes between SS patients and healthy controls were determined. GO and KEGG analysis showed that most of the DEGs were enriched in the ligand-receptor signaling pathways. PPI network construction was used to identify the hub genes of the DEGs. MYC, ANXA2, GDF15, AGTR1, NAMPT, LEPR, IGFBP-2, IL1RN, MMP7, and APLNR were identified as hub genes, and IGFBP-2 expression was found to be reversely associated with hepatic steatosis, fasting insulin, HOMA-IR index, and ALT levels. In HFD-fed mice, hepatic IGFBP-2 was also downregulated and negatively associated with hepatic triglyceride (TG) levels. Moreover, overexpression of IGFBP-2 ameliorated the oleate induced accumulation of TGs in hepatocytes.

CONCLUSIONS

This study identified novel gene signatures in the hepatic steatosis and will provide new understanding and molecular clues of hepatic steatosis.

摘要

背景与目的

非酒精性脂肪性肝病(NAFLD)已成为全球常见的慢性肝病。单纯性脂肪肝(SS)是NAFLD的早期阶段。然而,脂肪肝发生发展的分子机制尚未完全阐明。

方法

通过基因表达综合数据库(GEO)使用两个公开数据集(GSE48452和GSE89632)来鉴定脂肪肝发生过程中的差异表达基因(DEGs)。本研究共纳入72名参与者,包括38名组织学正常对照者和34名SS患者。进行基因本体论(GO)、京都基因与基因组百科全书(KEGG)以及蛋白质-蛋白质相互作用(PPI)网络分析以探究DEGs的功能。在高脂饮食(HFD)喂养的小鼠和油酸处理的HepG2细胞中进一步验证结果。

结果

确定了SS患者与健康对照者之间共有57个DEGs,其中31个上调基因和26个下调基因。GO和KEGG分析表明,大多数DEGs富集于配体-受体信号通路。使用PPI网络构建来鉴定DEGs的枢纽基因。MYC、ANXA2、GDF15、AGTR1、NAMPT、LEPR、IGFBP-2、IL1RN、MMP7和APLNR被鉴定为枢纽基因,并且发现IGFBP-2表达与肝脂肪变性、空腹胰岛素、HOMA-IR指数和ALT水平呈负相关。在HFD喂养的小鼠中,肝脏IGFBP-2也下调,并且与肝脏甘油三酯(TG)水平呈负相关。此外,IGFBP-2的过表达改善了油酸诱导的肝细胞内TG积累。

结论

本研究在肝脂肪变性中鉴定出了新的基因特征,将为肝脂肪变性提供新的认识和分子线索。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/11013ee59717/EC-21-0353fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/cdca1d5c806e/EC-21-0353fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/0b11f51a416a/EC-21-0353fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/984abbb64933/EC-21-0353fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/ac242483cff2/EC-21-0353fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/64b54320deb4/EC-21-0353fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/90d9cb4cb411/EC-21-0353fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/11013ee59717/EC-21-0353fig7.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/cdca1d5c806e/EC-21-0353fig1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/0b11f51a416a/EC-21-0353fig2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/984abbb64933/EC-21-0353fig3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/ac242483cff2/EC-21-0353fig4.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/64b54320deb4/EC-21-0353fig5.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/90d9cb4cb411/EC-21-0353fig6.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/aa4e/8562889/11013ee59717/EC-21-0353fig7.jpg

相似文献

1
IGFBP-2 as a biomarker in NAFLD improves hepatic steatosis: an integrated bioinformatics and experimental study.IGFBP-2作为非酒精性脂肪性肝病的生物标志物可改善肝脂肪变性:一项综合生物信息学与实验研究
Endocr Connect. 2021 Oct 13;10(10):1315-1325. doi: 10.1530/EC-21-0353.
2
[Analysis of hub genes and molecular mechanisms in non-alcoholic steatohepatitis based on the gene expression omnibus database].基于基因表达综合数据库的非酒精性脂肪性肝炎中枢纽基因及分子机制分析
Zhonghua Yi Xue Za Zhi. 2021 Nov 2;101(40):3317-3322. doi: 10.3760/cma.j.cn112137-20210416-00913.
3
Integrated Analysis of Multiple Microarray Studies to Identify Novel Gene Signatures in Non-alcoholic Fatty Liver Disease.整合多项微阵列研究以鉴定非酒精性脂肪性肝病中的新型基因特征
Front Endocrinol (Lausanne). 2019 Aug 30;10:599. doi: 10.3389/fendo.2019.00599. eCollection 2019.
4
Corilagin prevents non-alcoholic fatty liver disease improving lipid metabolism and glucose homeostasis in high fat diet-fed mice.柯里拉京可预防非酒精性脂肪性肝病,改善高脂饮食喂养小鼠的脂质代谢和葡萄糖稳态。
Front Nutr. 2022 Aug 17;9:983450. doi: 10.3389/fnut.2022.983450. eCollection 2022.
5
Integration analysis identifies the role of metallothionein in the progression from hepatic steatosis to steatohepatitis.整合分析确定了金属硫蛋白在从肝脂肪变性到脂肪性肝炎进展中的作用。
Front Endocrinol (Lausanne). 2022 Oct 18;13:951093. doi: 10.3389/fendo.2022.951093. eCollection 2022.
6
Identification of key pathways and genes in nonalcoholic fatty liver disease using bioinformatics analysis.运用生物信息学分析鉴定非酒精性脂肪性肝病中的关键通路和基因
Arch Med Sci. 2020 Mar 2;16(2):374-385. doi: 10.5114/aoms.2020.93343. eCollection 2020.
7
The molecular basis of the associations between non-alcoholic fatty liver disease and colorectal cancer.非酒精性脂肪性肝病与结直肠癌之间关联的分子基础。
Front Genet. 2022 Dec 9;13:1007337. doi: 10.3389/fgene.2022.1007337. eCollection 2022.
8
and Promote Non-alcoholic Steatohepatitis Progression Based on Bioinformatics Analysis and Experimental Studies.基于生物信息学分析和实验研究促进非酒精性脂肪性肝炎进展
Front Med (Lausanne). 2022 Apr 19;9:862278. doi: 10.3389/fmed.2022.862278. eCollection 2022.
9
Bioinformatics analysis reveals novel core genes associated with nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.生物信息学分析揭示了与非酒精性脂肪性肝病和非酒精性脂肪性肝炎相关的新核心基因。
Gene. 2020 Jun 5;742:144549. doi: 10.1016/j.gene.2020.144549. Epub 2020 Mar 14.
10
NUSAP1 Could be a Potential Target for Preventing NAFLD Progression to Liver Cancer.NUSAP1可能是预防非酒精性脂肪性肝病进展为肝癌的潜在靶点。
Front Pharmacol. 2022 Apr 1;13:823140. doi: 10.3389/fphar.2022.823140. eCollection 2022.

引用本文的文献

1
Serum insulin-like growth factor binding protein 2 is associated with hepatic steatosis in adults with metabolic dysfunction-associated steatotic liver disease.血清胰岛素样生长因子结合蛋白2与代谢功能障碍相关脂肪性肝病成人患者的肝脂肪变性有关。
Endocr Connect. 2025 Jul 17;14(7). doi: 10.1530/EC-25-0285. Print 2025 Jul 1.
2
GDF15 Circulating Levels Are Associated with Metabolic-Associated Liver Injury and Atherosclerotic Cardiovascular Disease.生长分化因子15循环水平与代谢相关肝损伤及动脉粥样硬化性心血管疾病相关。
Int J Mol Sci. 2025 Feb 26;26(5):2039. doi: 10.3390/ijms26052039.
3
A prognostic molecular signature of hepatic steatosis is spatially heterogeneous and dynamic in human liver.

本文引用的文献

1
NAFLD, Insulin Resistance, and Diabetes Mellitus Type 2.非酒精性脂肪性肝病、胰岛素抵抗和 2 型糖尿病。
Can J Gastroenterol Hepatol. 2021 Feb 17;2021:6613827. doi: 10.1155/2021/6613827. eCollection 2021.
2
Serum matrix metalloproteinase 7 (MMP7) is a biomarker of fibrosis in patients with non-alcoholic fatty liver disease.血清基质金属蛋白酶 7(MMP7)是一种非酒精性脂肪性肝病患者纤维化的生物标志物。
Sci Rep. 2021 Feb 3;11(1):2858. doi: 10.1038/s41598-021-82315-z.
3
Circulating IGFBP-2 levels are inversely associated with the incidence of nonalcoholic fatty liver disease: A cohort study.
肝脂肪变性的预后分子特征在人类肝脏中具有空间异质性且是动态变化的。
Cell Rep Med. 2024 Dec 17;5(12):101871. doi: 10.1016/j.xcrm.2024.101871. Epub 2024 Dec 9.
4
IGFBP2 functions as an endogenous protector against hepatic steatosis via suppression of the EGFR-STAT3 pathway.IGFBP2 通过抑制 EGFR-STAT3 通路发挥内源保护作用,防止肝脂肪变性。
Mol Metab. 2024 Nov;89:102026. doi: 10.1016/j.molmet.2024.102026. Epub 2024 Sep 17.
5
Combination of Waist Circumference and Circulating Levels of IGFBP-2 as a Simple Screening Tool for Early Detection of Metabolic Dysfunction-Associated Steatotic Liver Disease.腰围与胰岛素样生长因子结合蛋白-2循环水平联合作为早期检测代谢功能障碍相关脂肪性肝病的简单筛查工具
Diabetes Metab Syndr Obes. 2024 Sep 5;17:3335-3341. doi: 10.2147/DMSO.S466051. eCollection 2024.
6
Genotype-First Approach Identifies an Association between rs28374544/FOG2 and Liver Disease through Alterations in mTORC1 Signaling.基于基因型的研究方法发现,mTORC1 信号通路的改变与 rs28374544/FOG2 之间存在关联,进而影响肝脏疾病。
Genes (Basel). 2024 Aug 21;15(8):1098. doi: 10.3390/genes15081098.
7
Adipose tissue macrophage infiltration and hepatocyte stress increase GDF-15 throughout development of obesity to MASH.脂肪组织巨噬细胞浸润和肝细胞应激会增加肥胖发展过程中的 GDF-15,进而导致 MASH。
Nat Commun. 2024 Aug 21;15(1):7173. doi: 10.1038/s41467-024-51078-2.
8
The identification of a novel shared therapeutic target and drug across all insulin-sensitive tissues under insulin resistance.在胰岛素抵抗状态下,识别所有胰岛素敏感组织中一种新的共同治疗靶点和药物。
Front Nutr. 2024 Mar 26;11:1381779. doi: 10.3389/fnut.2024.1381779. eCollection 2024.
9
Comprehensive meta-analysis reveals distinct gene expression signatures of MASLD progression.综合荟萃分析揭示了 MASLD 进展的独特基因表达特征。
Life Sci Alliance. 2024 Apr 2;7(6). doi: 10.26508/lsa.202302517. Print 2024 Jun.
10
Exploring the Multifaceted Landscape of MASLD: A Comprehensive Synthesis of Recent Studies, from Pathophysiology to Organoids and Beyond.探索代谢相关脂肪性肝病的多维度图景:从病理生理学到类器官及其他领域的近期研究综合概述
Biomedicines. 2024 Feb 8;12(2):397. doi: 10.3390/biomedicines12020397.
循环 IGFBP-2 水平与非酒精性脂肪性肝病的发生率呈负相关:一项队列研究。
J Int Med Res. 2020 Aug;48(8):300060520935219. doi: 10.1177/0300060520935219.
4
Physiological Disturbance in Fatty Liver Energy Metabolism Converges on IGFBP2 Abundance and Regulation in Mice and Men.脂肪肝能量代谢中的生理紊乱在小鼠和人类中汇聚于 IGFBP2 的丰度和调控。
Int J Mol Sci. 2020 Jun 10;21(11):4144. doi: 10.3390/ijms21114144.
5
ARRB1 inhibits non-alcoholic steatohepatitis progression by promoting GDF15 maturation.ARRB1通过促进生长分化因子15(GDF15)成熟来抑制非酒精性脂肪性肝炎的进展。
J Hepatol. 2020 May;72(5):976-989. doi: 10.1016/j.jhep.2019.12.004. Epub 2019 Dec 16.
6
Landscape of Intercellular Crosstalk in Healthy and NASH Liver Revealed by Single-Cell Secretome Gene Analysis.单细胞分泌组基因分析揭示健康和 NASH 肝脏中的细胞间串扰景观。
Mol Cell. 2019 Aug 8;75(3):644-660.e5. doi: 10.1016/j.molcel.2019.07.028.
7
The mTORC2-Akt1 Cascade Is Crucial for c-Myc to Promote Hepatocarcinogenesis in Mice and Humans.mTORC2-Akt1 级联反应对于 c-Myc 促进小鼠和人类肝癌发生至关重要。
Hepatology. 2019 Nov;70(5):1600-1613. doi: 10.1002/hep.30697. Epub 2019 Jun 21.
8
The apelin/APJ system as a therapeutic target in metabolic diseases.阿皮林/APJ 系统作为代谢性疾病的治疗靶点。
Expert Opin Ther Targets. 2019 Mar;23(3):215-225. doi: 10.1080/14728222.2019.1561871. Epub 2019 Jan 10.
9
GDF15 and Growth Control.生长分化因子15与生长调控
Front Physiol. 2018 Nov 27;9:1712. doi: 10.3389/fphys.2018.01712. eCollection 2018.
10
Growth differentiation factor 15 ameliorates nonalcoholic steatohepatitis and related metabolic disorders in mice.生长分化因子 15 可改善小鼠的非酒精性脂肪性肝炎及相关代谢紊乱。
Sci Rep. 2018 May 1;8(1):6789. doi: 10.1038/s41598-018-25098-0.